The Philips 3D intracardiac echocardiography catheter is ready for its close-up, that is, its extreme close-up in vivo.
Just under a year after obtaining 510 (k) clearance from the FDA, the VeriSight Pro treated its first patient outside of clinical trials. A surgical team from the Mayo Clinic used the catheter, which captures echocardiograms to map the interior of the heart, during a left atrial appendage occlusion procedure.
In this procedure, a sac embedded in the wall of the left atrium, known as the left atrial appendage, is sealed to prevent blood clots from traveling to the heart itself. It typically requires an ultrasound probe to be passed through a sedated patient’s throat and into the esophagus to provide live imaging.
With the VeriSight Pro, however, that same imaging technology has been scaled down to fit the end of a three-millimeter catheter that is inserted into an artery in the neck, arm, or groin. The patient does not need to be sedated, which eliminates the risks and restrictions associated with general anesthesia.
Once the catheter reaches the patient’s heart, it uses intracardiac echocardiography technology to deliver real-time 2D and 3D imaging data. These images are transmitted to the monitors of the Philips EPIQ CVx cardiac ultrasound system to help guide cardiologists through their procedures.
RELATED: Philips Offers New MRI Method Allows Total Heart Scans in Less Than a Minute
VeriSight Pro’s real-time imaging tools include the ability to view two 3D scan planes at the same time, allowing, for example, a cardiologist to simultaneously assess both axes of the left atrial appendage to determine which device must be used to close it.
The system also provides high quality 2D images of the structures, valves and blood flow inside the heart. Because of the way the camera is positioned on the end of the catheter, doctors can capture images from multiple views and angles inside the heart without having to manually reposition the catheter.
The VeriSight Pro is designed for use in minimally invasive procedures in structural heart disease and electrophysiology. The device is currently only available on a limited basis in the United States
“Next-generation” technology can transform some complicated procedures, said Mohamad Adnan Alkhouli, the interventional cardiologist at the Mayo Clinic who performed the first procedure with the VeriSight Pro. On the one hand, this makes the occlusion of the left atrial appendage accessible to many patients who are not good candidates for general anesthesia, he said.
Alkhouli also noted that the catheter’s âexcellent tricuspid valve imagingâ also makes it a more effective treatment tool for tricuspid regurgitation, in which a defective valve allows blood to return to the upper right chamber of the heart.
RELATED: Philips SmartCT 3D Imaging Software Gets FDA Clearance
Philips has been on a roll in the Image Guided Therapy department over the past few months. In April, it obtained FDA clearance for SmartCT imaging software, which integrates with the recently relaunched Azurion platform to guide physicians in capturing and analyzing 3D scans collected by angiography, neurology, soft tissue imaging and guidewire navigation.
In the same month, Philips announced massive gains in its diagnostic and treatment business for the first quarter of 2021. With an 11% increase in orders during the period, this segment generated an impressive revenue of 2 , $ 24 billion, which led Philips to adopt more optimistic projections. for its post-COVID recovery.